Press releases

18 October, 2017

NeuroVive and Lund University Collaboration Receives Grant for Liver Cancer Research

Lund, Sweden, 18 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that NeuroVive and Ramin Massoumi at Lund Univers ...

5 October, 2017

NeuroVive’s collaborator the Children’s Hospital of Philadelphia awarded NIH grant to study NVP015 against chemical threats

Lund, Sweden, 5 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF, the mitochondrial medicine company, today announced that its research collaboration partner the Childre ...

4 October, 2017

NeuroVive appoints Daniel Schale as Director of Communications

Lund 4 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced the appointment of Daniel Schale as Director of Communicati ...

3 October, 2017

NeuroVive presents innovative metabolic regulators for NASH. Abstract selected as top tier at The Liver Meeting 2017

Lund, Sweden, 3 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with new preclinical data related ...

21 September, 2017

Regulatory

NeuroVive receives positive EMA Scientific Advice on its NeuroSTAT development plan for TBI

Lund, Sweden, 21 September 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced positive feedback on its requested Scientific A ...

1 September, 2017

NeuroVive appoints Mark Farmery as Vice President Business Development

Lund, Sweden, September 1, 2017 - NeuroVive Pharmaceutical AB ("NeuroVive" or "the company", Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced the appointment o ...

17 August, 2017

Regulatory

NeuroVive Pharmaceutical AB Interim report January – June 2017

Strategic in-licensing broadens the project portfolio

31 July, 2017

Regulatory

Number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, July 31, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in Ne ...

18 July, 2017

Regulatory

NeuroVive signs private placement agreement with Esousa Holdings LLC and issues units

Lund, Sweden, 18 July 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) is pleased to announce that it has signed a non-brokered private placement agreement (the "Placement") wi ...

27 June, 2017

Regulatory

NeuroVive and Yungjin Pharm start clinical development in genetic mitochondrial disease

Lund, Sweden and Seoul, South Korea, 27 June 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today ann ...

1 June, 2017

Regulatory

NeuroVive receives research grant from Vinnova for development of the NVP015 genetic mitochondrial disease project

Lund, Sweden, 1 June 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company receives close to 1 million SEK in a research grant from Swedish innovati ...

23 May, 2017

Regulatory

NeuroVive to continue NeuroSTAT® clinical development after positive outcome in preclinical and clinical TBI studies

Lund, Sweden, 23 May 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced positive results from clinical and preclinical studies with its drug NeuroSTAT® for the pr ...